SIETES :: 93212 citas

Resultados de la búsqueda por DERMATOLÓGICOS REFINAR BÚSQUEDA

1.

Boulware DR, Pullen MF, Bangdiwala AS, Pastik KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, et al.. A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19. N Engl J Med 2020;383:3 de junio. [Ref.ID 103646]

2.

Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ 2020;369:8 de abril. [Ref.ID 103595]

3.

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure F-X, Nicastri E, Oda R, et al.. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020;382:11 de junio. [Ref.ID 103581]

4.

Yang M-S, Lee JY, Kim J, Kim G-W, Kim B-K, Kim Y, Park H-W, Cho S-H, Min K-U, Kang H-R. Searching for the culprit drugs for Stevens-Johnson syndrome and toxic epidermal necrolysis from a nationwide claim database in Korea. J Allergy Clin Immunol 2020;8:febrero. [Ref.ID 103535]

5.

Castells M, Khan DA, Phillips EJ. Penicillin allergy. N Engl J Med 2019;381:12 de diciembre. [Ref.ID 103229]

6.

Anónimo. Insect repellents. Med Lett Drugs Ther 2019;61:26 de agosto. [Ref.ID 103164]

7.

Anónimo. Ginkgo biloba: to be avoided due to severe adverse effects. Prescrire Int 2019;28:. [Ref.ID 103129]

8.

Anónimo. Sulfonamide cross-reactivity. The Medical Letter on Drug and Therapeutics Bulletin 2019;61:25 de marzo. [Ref.ID 103061]

9.

Frey N, Bodmer M, Bircher A, Jick SS, Meier CR, Spoendlin J. Stevens–Johnson syndrome and toxic epidermal necrolysis in association with commonly prescribed drugs in outpatient care other than anti-epileptic drugs and antibiotics: a population-based case–control study. Drug Saf 2019;42:enero. [Ref.ID 103028]

10.

Rodríguez-Martín S, Martín-Merino E, Lerma V, Rodríguez-Miguel A, González O. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. Eur J Clin Pharmacol 2019;75:febrero. [Ref.ID 103013]

11.

Costa CS, Bagatin E, Martimbianco ALC, da Silva EMK, Lúcio MM, Magin P, Riera R. Oral isotretinoin for acne. Cochrane Database of Systematic Reviews 2018:24 de noviembre. [Ref.ID 102889]

12.

Xu C, Chen Y-P, Du X-J, Liu J-Q, Huang C-L, Chen L, Zhou G-Q, Li W-F, Mao Y-P, Hsu C, Liu Q, Lin A-H, Tang L-L, Sun Y, Ma J. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 2018;363:8 de noviembre. [Ref.ID 102847]

13.

Pottegård A, Pedersen SA, Alba S, Schmidt J, Hölmich LR, Friis S, Gaist D. Association of hydrochlorothiazide use and risk of malignant melanoma. JAMA Intern Med 2018;178:1120-2. [Ref.ID 102645]

14.

Maya Y, Ota M. Drug-induced localised scleroderma. BMJ 2018;360:12 de abril. [Ref.ID 102643]

15.

Tangamornsuksan W, Lohitnavy M. Association between HLA-B*1301 and dapsone-induced cutaneous adverse drug reactions: a systematic review and meta-analysis. JAMA Dermatol 2018;154:1 de abril. [Ref.ID 102558]

16.

Imatoh T, Sai K, Fukasawa C, Hinomura Y, Nakamura R, Okamoto-Uchida Y, Segawa K, Saito Y. Association between infection and severe drug adverse reactions: an analysis using data from the Japanese Adverse Drug Event Report database. Eur J Clin Pharmacol 2017;73:1643-53. [Ref.ID 102180]

17.

Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]

18.

Anónimo. Fingolimod (Gilenya): nuevas contraindicaciones de uso en pacientes con patología cardiaca subyacente y recomendaciones de revisiones dermatológicas. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2017:6 de noviembre. [Ref.ID 102124]

19.

Trubiano JA, Adkinson NF, Phillips EJ. Penicillin allergy Is not necessarily forever. JAMA 2017;318:82-3. [Ref.ID 102053]

20.

Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorenzton M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017:11 de septiembre. [Ref.ID 102052]